Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Author Correction: Advancing equitable access to innovation in breast cancer.

NPJ breast cancer·2025
Same author

Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Advancing equitable access to innovation in breast cancer.

NPJ breast cancer·2025
Same author

Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers.

NPJ breast cancer·2024

Related Experiment Video

Updated: Jul 23, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.3K

Systemic Therapy in Older Patients With High-Risk Disease.

Etienne G C Brain1

  • 1Department of Medical Oncology, Institut Curie, Saint-Cloud, France.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|July 12, 2023
PubMed
Summary

Adjuvant treatments for older breast cancer patients need adjustments due to frailty and side effect risks. Geriatric assessments and patient preferences are crucial for personalized, effective care, improving quality of life.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.0K

Related Experiment Videos

Last Updated: Jul 23, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.0K

Area of Science:

  • Geriatric Oncology
  • Breast Cancer Therapeutics
  • Clinical Decision-Making

Background:

  • Adjuvant systemic treatments for older breast cancer patients often require dose or schedule modifications compared to younger individuals.
  • Frailty, common in patients over 70, increases the risk of adverse events from chemotherapy, endocrine therapy, and targeted treatments.
  • Pharmacokinetics can be misleading in older adults due to age-related declines in functional reserves.

Purpose of the Study:

  • To highlight the challenges and necessary adjustments in adjuvant systemic treatments for older breast cancer patients.
  • To emphasize the importance of geriatric assessment and patient-centered care in optimizing treatment decisions.
  • To advocate for integrating molecular testing with geriatric factors for comprehensive adjuvant treatment planning.

Main Methods:

  • Review of challenges in adjuvant therapy for older breast cancer patients, including frailty, side effects, and pharmacokinetic alterations.
  • Analysis of the impact of geriatric assessment on treatment decisions, noting significant changes and de-escalation rates.
  • Consideration of patient expectations, quality of life, and the role of multimorbidity in treatment outcomes.

Main Results:

  • Geriatric assessment integrated into multidisciplinary teams led to 30%-50% changes in treatment decisions, de-escalating therapy in two-thirds of cases.
  • Older patients prioritize functionality, cognitive health, and independence, often conflicting with standard dose-intensity models.
  • Molecular testing for high-risk tumors should be combined with geriatric factors for better adjuvant treatment selection.

Conclusions:

  • Adjuvant treatment decisions for older breast cancer patients must account for frailty, comorbidities, and individual patient goals, prioritizing quality of life.
  • A shift from age-agnostic protocols to personalized approaches, incorporating geriatric evaluations and patient preferences, is essential.
  • Combining advanced molecular diagnostics with comprehensive geriatric assessments offers a more holistic strategy for optimizing adjuvant therapy in elderly breast cancer survivors.